Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial

Brooklyn, T N, Dunnill, M G S, Shetty, A, Bowden, J J, Williams, J D L, Griffiths, C E M, Forbes, A ORCID: https://orcid.org/0000-0001-7416-9843, Greenwood, R and Probert, C S (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut, 55 (4). pp. 505-509. ISSN 0017-5749

Full text not available from this repository. (Request a copy)

Abstract

Pyoderma gangrenosum (PG) is a chronic ulcerating skin condition that often occurs in association with inflammatory bowel disease. There have been a number of reports of PG responding to infliximab, a monoclonal antibody against tumour necrosis factor alpha.

Item Type:	Article
Uncontrolled Keywords:	adult,aged,aged, 80 and over,antibodies, monoclonal,dermatologic agents,double-blind method,female,humans,inflammatory bowel diseases,male,middle aged,pyoderma gangrenosum,quality of life,treatment outcome
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology Faculty of Medicine and Health Sciences > Research Groups > Nutrition and Preventive Medicine
Depositing User:	Pure Connector
Date Deposited:	06 Aug 2014 10:38
Last Modified:	20 Oct 2022 19:30
URI:	https://ueaeprints.uea.ac.uk/id/eprint/49644
DOI:	10.1136/gut.2005.074815

Actions (login required)

View Item